Sanofi SA vs Wix.Com Ltd — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while Wix.Com Ltd trades at $76.56 (market cap $3.11B). The key difference: Sanofi SA is far larger — about 30.6× Wix.Com Ltd's market cap, and Sanofi SA pays a 6.01% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Wix.Com Ltd for 62 Days on average.
| SNY | WIX | |
|---|---|---|
Market Cap | $95.18B | $3.11B |
Volume | 2,995,646 | 809,286 |
Sector | Health | Technology |
52-Week High | $52.34 | $145.54 |
52-Week Low | $39.51 | $40.43 |
Typical Hold Time | 94 Days | 62 Days |
Enterprise Value | $114.48B | $4.19B |
Dividend Yield | 6.01% | — |
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
WIX stock trades at $74.13, up 1.59% today, with a neutral technical signal and bullish moving averages. Revenue grew to $1.99B in 2025, but net income margin is negative at -8.19%. The company faces a securities class action lawsuit, with multiple law firms announcing deadlines in late September 2026. Analyst consensus is a Buy with a $77.00 price target, though valuation ratios like P/E of 62.84 appear elevated.
The outlook is mixed: strong revenue growth and positive cash flow from operations support the bullish analyst stance, but legal risks and negative profitability margins pose significant headwinds. Upside depends on sustained earnings beats and resolution of litigation, while downside risks include prolonged negative margins and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →